Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
Globe Newswire•12/10/2026•16:05 ET
0
Key Highlights
- ➤Patent protection targets late 2040s for pelareorep’s covered therapeutic applications
- ➤Existing manufacturing patent protection extends through 2044
- ➤Three patent application families remain pending, including multiple method-of-use patents
- ➤U.S. Track One application expected this quarter for immunologic-response therapy use
- ➤Composition-of-matter patent planned for modified “next generation” pelareorep
Expert Statements
Jared Kelly, Chief Executive Officer of Oncolytics
“We are expanding our patent portfolio to protect how pelareorep is manufactured, how it is used to treat cancer, and the innovations that could define its next generation”
Jared Kelly, Chief Executive Officer of Oncolytics
“Our existing manufacturing protection through 2044 provides a strong foundation. The additional method of use patents and potential new composition of matter protection are intended to extend that foundation into the late 2040s and support the long-term development and commercial potential of pelareorep.”
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term
Three patent applications are pending, including two method of use with one expected to be converted to a Track One application this quarter
Get started
Create a free account to read the full story.